Although IL-7 was known to promote the T-ALL proliferation [41] and mutational activation of IL-7Rα was reported to promote the development of T-ALL [42], we did not observe increased tumor burden or decreased survival with rhIL-7-hyFc treatment alone in either CTCL or T-ALL PDX models. This evidence concerns the gene IL7 and neoplasm.